ArticleJournal of Crohn's & colitis2016
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.
Article in Journal of Crohn's & colitis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02852694 (Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease), which is not on this map. Cited by 74 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate Vs Azathioprine or Adalimumab for Maintaining Remission in Patients At Low or High Risk for Aggressive Disease Course, Respectively-a Treatment Strategy
Who cites it
74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Evaluating the role of sarcopenia in adverse clinical outcomes for Crohn's disease patients: a systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review.Health technology assessment (Winchester, England) · 2021Pooled it
- ACG Clinical Guideline: Management of Crohn's Disease in Adults.The American journal of gastroenterology · 2018Guideline
- Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.The American journal of gastroenterology · 2026Article
- Tissue transcriptional programs stratify Crohn's disease by therapeutic response and clinical outcomes.Scientific reports · 2026Article
- Biologic Therapy and Surgical Management in Crohn's Disease: Postoperative Outcomes and Biologic Management Patterns in a Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts.Gastroenterology report · 2026Review
- Prevalence, Clinical Characteristics, and Predictors of Difficult-to-Treat Inflammatory Bowel Disease in a Real-World Taiwanese Cohort.Life (Basel, Switzerland) · 2026Article
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2024 for the Clinical Practice of Inflammatory Bowel Disease-Associated Intestinal Neoplasia (English Version).Journal of the anus, rectum and colon · 2026Review
- Explainable random forest-SHAP framework for Montreal phenotype-stratified prediction of one-year complications in Crohn's disease.Frontiers in physiology · 2026Article
- Prediction of Relapse and Steroid Dependency in Pediatric Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2025Article
- A Guide to the Patient-Centric Use of Vedolizumab for Crohn's Disease.Inflammatory bowel diseases · 2025Review
- Misinterpretation and misapplication of biomarkers in inflammatory bowel disease: how do we avoid this?Expert review of gastroenterology & hepatology · 2025Review
- Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?Biomedicines · 2025Article
- Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions.Journal of clinical medicine · 2025Article
- The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.Inflammatory bowel diseases · 2024Article
- Ten-year outcomes of a prospective population-based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand.JGH open : an open access journal of gastroenterology and hepatology · 2024Article
- Farming Activities and Risk of Inflammatory Bowel Disease: A French Nationwide Population-based Cohort Study.Journal of Crohn's & colitis · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2016
Authors and funding
12 authors at 11 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsEfforts to slow or prevent the progressive course of inflammatory bowel diseases [IBD] include early and intensive monitoring and treatment of patients at higher risk for complications. It is therefore essential to identify high-risk patients - both at diagnosis and throughout disease course.
methodsAs a part of an IBD Ahead initiative, we conducted a comprehensive literature review to identify predictors of long-term IBD prognosis and generate draft expert summary statements. Statements were refined at national meetings of IBD experts in 32 countries and were finalized at an international meeting in November 2014.
resultsPatients with Crohn's disease presenting at a young age or with extensive anatomical involvement, deep ulcerations, ileal/ileocolonic involvement, perianal and/or severe rectal disease or penetrating/stenosing behaviour should be regarded as high risk for complications. Patients with ulcerative colitis presenting at young age, with extensive colitis and frequent flare-ups needing steroids or hospitalization present increased risk for colectomy or future hospitalization. Smoking status, concurrent primary sclerosing cholangitis and concurrent infections may impact the course of disease. Current genetic and serological markers lack accuracy for clinical use.
conclusionsSimple demographic and clinical features can guide the clinician in identifying patients at higher risk for disease complications at diagnosis and throughout disease course. However, many of these risk factors have been identified retrospectively and lack validation. Appropriately powered prospective studies are required to inform algorithms that can truly predict the risk for disease progression in the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.